In fact, the problems of treating cardiovascular diseases from MSCs have been clearly described previously,328 including (1) lack of assessment of the potential of MSCs transdifferentiation into functional cardiac and endothelial cells in vitro,329 (2) uncontrolled differentiation of MSCs into undesirable cell types after administration,330 and (3) indistinguishable nature MSCs obtained from different sources, with different levels of differentiation potential.331 so, the use of MSC-based therapy in cardiovascular diseases still at the initial stage|early stage|with recent infection}, and <a href=http://capriccio3.com/?p=1203>http://capriccio3.com/?p=1203</a> brings potential benefits to patients.